MX347890B - Neuroproteccion y reparacion de melina usando progestina. - Google Patents

Neuroproteccion y reparacion de melina usando progestina.

Info

Publication number
MX347890B
MX347890B MX2012004542A MX2012004542A MX347890B MX 347890 B MX347890 B MX 347890B MX 2012004542 A MX2012004542 A MX 2012004542A MX 2012004542 A MX2012004542 A MX 2012004542A MX 347890 B MX347890 B MX 347890B
Authority
MX
Mexico
Prior art keywords
neurodegeneration
compound
myelin repair
treating
nestorone
Prior art date
Application number
MX2012004542A
Other languages
English (en)
Other versions
MX2012004542A (es
Inventor
Regine Sitruk-Ware
Michael Maria Helmut Schumacher
Martine El-Etr
Abdelmouman Ghoumari
Rachida Guennoun
Roberta Brinton
Original Assignee
The Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Population Council Inc filed Critical The Population Council Inc
Publication of MX2012004542A publication Critical patent/MX2012004542A/es
Publication of MX347890B publication Critical patent/MX347890B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una dosis farmacéuticamente efectiva de 5mg/día o inferior de 16-metileno-17 a-acetoxi-19-norpregn-4-eno-30,20-diona para usarse para la regeneración de mielina en un recipiente, en donde dicha dosis farmacéuticamente eficaz de un compuesto de progestina ejerce la unión a receptores de progesterona sin la interacción con el receptor de andrógeno y sin inducir respuestas biológicas de andrógeno o glucocorticoide.
MX2012004542A 2009-10-19 2010-10-19 Neuroproteccion y reparacion de melina usando progestina. MX347890B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932009P 2009-10-19 2009-10-19
PCT/US2010/053201 WO2011049948A2 (en) 2009-10-19 2010-10-19 Neuroprotection and myelin repair using nestorone®

Publications (2)

Publication Number Publication Date
MX2012004542A MX2012004542A (es) 2012-11-29
MX347890B true MX347890B (es) 2017-05-18

Family

ID=43413545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004542A MX347890B (es) 2009-10-19 2010-10-19 Neuroproteccion y reparacion de melina usando progestina.

Country Status (9)

Country Link
US (1) US10052335B2 (es)
EP (1) EP2490680B1 (es)
JP (1) JP5871807B2 (es)
AU (1) AU2010308308B2 (es)
BR (1) BR112012009306A2 (es)
CA (1) CA2777551C (es)
ES (1) ES2669694T3 (es)
MX (1) MX347890B (es)
WO (1) WO2011049948A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2669694T3 (es) 2009-10-19 2018-05-28 The Population Council, Inc. Neuroprotección y reparación de mielina usando Nestorone®
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
NZ600907A (en) * 2009-12-17 2013-11-29 Population Council Inc Progestin/estradiol transdermal gel
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
WO2012129365A1 (en) 2011-03-22 2012-09-27 The Population Council, Inc. Myelin regeneration with androgens
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102688247A (zh) * 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US9808470B2 (en) * 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2836388A1 (en) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection and myelin repair using st-1435
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
WO2015088625A2 (en) * 2013-09-25 2015-06-18 Case Western Reserve University Compounds and methods of promoting myelination
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
WO2016005599A1 (en) * 2014-07-10 2016-01-14 Biocopea Limited Compositions, methods and uses for treating gender-biased immune disorders
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4760092A (en) * 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
EP1263484B1 (en) 2000-03-15 2007-05-16 OrbusNeich Medical, Inc. Coating which promotes endothelial cell adherence
US6891081B1 (en) 2000-08-14 2005-05-10 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing amyloid-beta alcohol dehydrogenase (ABAD) in brain as model of alzheimer's disease and uses thereof
US8026228B2 (en) 2001-11-15 2011-09-27 Pantarhei Bioscience B.V. Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
AU2002365513A1 (en) * 2001-11-30 2003-06-10 Solvay Pharmaceuticals Gmbh Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
TW200400040A (en) 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US20040087563A1 (en) 2002-11-05 2004-05-06 Siegfried Mayerhofer Hormone replacement therapy with cardiovascular protection using antialdosteronic progestins
WO2006096404A2 (en) 2005-03-04 2006-09-14 Alsgen, Inc Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues
EP2164498A4 (en) * 2007-06-04 2010-09-08 Univ California PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ES2669694T3 (es) 2009-10-19 2018-05-28 The Population Council, Inc. Neuroprotección y reparación de mielina usando Nestorone®
CN102657661A (zh) 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
CN102688247A (zh) 2012-04-15 2012-09-26 温州医学院 Nestorone在制备治疗帕金森氏病的药物用途

Also Published As

Publication number Publication date
JP2013508379A (ja) 2013-03-07
US10052335B2 (en) 2018-08-21
WO2011049948A2 (en) 2011-04-28
AU2010308308A1 (en) 2012-06-07
MX2012004542A (es) 2012-11-29
AU2010308308B2 (en) 2013-11-28
EP2490680B1 (en) 2018-04-04
US20120231052A1 (en) 2012-09-13
BR112012009306A2 (pt) 2016-06-07
EP2490680A2 (en) 2012-08-29
JP5871807B2 (ja) 2016-03-01
WO2011049948A3 (en) 2011-06-16
CA2777551A1 (en) 2011-04-28
CA2777551C (en) 2015-12-22
WO2011049948A4 (en) 2011-08-04
ES2669694T3 (es) 2018-05-28

Similar Documents

Publication Publication Date Title
MX347890B (es) Neuroproteccion y reparacion de melina usando progestina.
WO2010088409A3 (en) Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2013078422A3 (en) Natural combination hormone replacement formulations and therapies
MX363536B (es) Gel transdermico de progestina/estradiol.
MX2020013533A (es) Formulaciones y terapias de reemplazo de combinacion de hormonas naturales.
PL2711371T3 (pl) Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun
GB201104241D0 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
NZ609420A (en) Fulvestrant compositions and methods of use
WO2009148620A3 (en) Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
WO2008021368A3 (en) Compositions and methods for neuroprotection
NZ597583A (en) Treatment of alzheimer’s disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
AU2009256009A8 (en) Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
WO2011059969A3 (en) Mammalian metabolites of steroids
IL208723A0 (en) Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
MX2010005119A (es) Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.
IL204629A0 (en) Use of glycerol, method of crop treatment, composition for tank mixing and a method of preparation of a composition for tank mixing
TW200726473A (en) Compositions and methods for treatment of cycle-related symptoms
WO2011037837A3 (en) Vaginal vault suspension device and method
PH12014500596A1 (en) Plant steroids and uses thereof
EP2661175A4 (en) COMBINATION STEROID AND GLUCOCORTICOID RECEPTORANT AGONIST THERAPY
SI1989217T1 (sl) 11-fosforni steroidni derivati, uporabni kot modulatorji progesteronskega receptorja
WO2011050008A9 (en) Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
PL2564900T3 (pl) Steroidy C-19 do zastosowań terapeutycznych
LT2120976T (lt) Analinio nelaikymo gydymo būdai naudojant mioblastus
WO2008147640A3 (en) Hormone replacement therapy

Legal Events

Date Code Title Description
FG Grant or registration